- CFO Spotlights
- Profiles
- Alex Kelly
Profile
Alex Kelly
Chief Financial Officer, Precision BioSciences, Inc.
Former. First published here October 28, 2026; built from records as of October 28, 2026.
Precision BioSciences, Inc. named Naresh Tanna to succeed Alex Kelly, effective August 1, 2026.1
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| Precision BioSciences, Inc. (DTIL) Biological Products, (No Diagnostic Substances) | Not stated | Former |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- August 1, 2026effective
Precision BioSciences, Inc. named Naresh Tanna to succeed Alex Kelly, effective August 1, 2026. Profile of Naresh Tanna.
Kelly’s promotion to Chief Operating Officer, the Board appointed Naresh Tanna, age 45, as Chief Financial Officer of the Company.
[1] Filing by Precision BioSciences, Inc., filed with the SEC on July 27, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Current report filed with the SEC, Precision BioSciences, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed July 27, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or Alex Kelly wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.